Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
Provided By GlobeNewswire
Last update: Aug 15, 2025
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial
- Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic
- Secured new service contract with EU biotech for Allarity Medical Laboratory
